- JP-listed companies
- ASKA Pharmaceutical Holdings CO., Ltd.
- Income statement
ASKA Pharmaceutical Holdings CO., Ltd.【JP:4886】Income statement
Market cap
¥71.1B
P/E ratio
14x
| 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 56,607 | 60,461 | 62,843 | 64,139 |
| Revenue growth (%) | - | |||
| Cost of revenue | 30,255 | 31,876 | 32,178 | 32,803 |
| Gross profit | 26,351 | 28,584 | 30,664 | 31,335 |
| Gross margin (%) | ||||
| Operating margin (%) | ||||
| Operating expenses | 21,556 | 23,476 | 24,164 | 26,003 |
| Operating income | 4,795 | 5,108 | 6,500 | 5,331 |
| Income before tax | 4,880 | 5,232 | 6,522 | 5,107 |
| Pretax margin (%) | 8.6 | 8.7 | 10.4 | 8 |
| Provision for income taxes | 1,873 | 1,118 | 2,316 | 1,091 |
| Effective tax rate (%) | ||||
| Net income | 4,290 | 4,238 | 7,545 | 5,101 |
| Net income margin (%) | ||||
| Earnings per share | 151.22 | 150.08 | 266.51 | 179.95 |
| Dividend per share | 15 | 16 | 40 | 55 |
| EBITDA | ||||
| EBITDA margin (%) |